PDCD1 and melanoma: The immune suppressive effects of TNFα have led to the TICIMEL phase 1b clinical trial evaluating the activity and safety of combination anti-TNFα and immune checkpoint inhibitors (anti-PD1 and anti-CTLA4) in advanced melanoma (NCT03293784).